Firebrick Pharma's CEO is Peter Molloy, appointed in Apr 2012, has a tenure of 14.25 years. total yearly compensation is A$355.89K, comprised of 79.7% salary and 20.3% bonuses, including company stock and options. directly owns 11.24% of the company’s shares, worth A$1.19M. The average tenure of the management team and the board of directors is 5.1 years and 7.6 years respectively.
Key information
Peter Molloy
Chief executive officer
AU$355.9k
Total compensation
CEO salary percentage
79.68%
CEO tenure
14.3yrs
CEO ownership
11.2%
Management average tenure
5.1yrs
Board average tenure
7.6yrs
Recent management updates
Recent updates
CEO Compensation Analysis
How has Peter Molloy's remuneration changed compared to Firebrick Pharma's earnings?
Date
Total Compensation
Salary
Company Earnings
Dec 31 2025
n/a
n/a
-AU$2m
Sep 30 2025
n/a
n/a
-AU$3m
Jun 30 2025
AU$356k
AU$284k
-AU$3m
Mar 31 2025
n/a
n/a
-AU$2m
Dec 31 2024
n/a
n/a
-AU$2m
Sep 30 2024
n/a
n/a
-AU$1m
Jun 30 2024
AU$296k
AU$284k
-AU$1m
Mar 31 2024
n/a
n/a
-AU$3m
Dec 31 2023
n/a
n/a
-AU$5m
Sep 30 2023
n/a
n/a
-AU$6m
Jun 30 2023
AU$351k
AU$284k
-AU$7m
Mar 31 2023
n/a
n/a
-AU$6m
Dec 31 2022
n/a
n/a
-AU$5m
Sep 30 2022
n/a
n/a
-AU$5m
Jun 30 2022
AU$324k
AU$252k
-AU$4m
Mar 31 2022
n/a
n/a
-AU$3m
Dec 31 2021
n/a
n/a
-AU$3m
Sep 30 2021
n/a
n/a
-AU$3m
Jun 30 2021
AU$140k
AU$140k
-AU$2m
Compensation vs Market: Peter's total compensation ($USD246.87K) is about average for companies of similar size in the Australian market ($USD318.96K).
Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.
CEO
Peter Molloy (72 yo)
14.3yrs
Tenure
AU$355,892
Compensation
Dr. Peter Laurence Molloy, BSc, MBA, FAICD, Ph D, is the Founder, Executive Chairman and Chief Executive Officer of Firebrick Pharma Limited since April 12, 2012. He served as Managing Director and Chief E...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Peter Molloy
Founder
14.3yrs
AU$355.89k
11.24% A$ 1.2m
Stephen Goodall
Founder
14.3yrs
AU$282.15k
10.92% A$ 1.2m
Kavi Bekarma
Chief Financial Officer
3.6yrs
no data
no data
Simon Tucker
Chief Scientific Officer
no data
no data
0.63% A$ 66.6k
Monique Baldwin
Head of Regulatory Affairs
4.6yrs
no data
no data
Nilesh Wadhwa
Head of Business Development & Licensing
less than a year
no data
no data
Stephen Buckley
Company Secretary
5.6yrs
no data
no data
5.1yrs
Average Tenure
Experienced Management: FRE's management team is seasoned and experienced (5.1 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Peter Molloy
Founder
14.3yrs
AU$355.89k
11.24% A$ 1.2m
Stephen Goodall
Founder
14.3yrs
AU$282.15k
10.92% A$ 1.2m
Al Moghaddam
Non-Executive Director
less than a year
no data
no data
Rick Legleiter
Independent Non-Executive Director
less than a year
no data
no data
7.6yrs
Average Tenure
67yo
Average Age
Experienced Board: FRE's board of directors are considered experienced (7.6 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/06 06:56
End of Day Share Price
2026/07/03 00:00
Earnings
2025/12/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Firebrick Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.